このアイテムのアクセス数: 77

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
journal.pone.0177375.pdf16.12 MBAdobe PDF見る/開く
タイトル: Calcification in dermal fibroblasts from a patient with GGCX syndrome accompanied by upregulation of osteogenic molecules
著者: Okubo, Yumi
Masuyama, Ritsuko
Iwanaga, Akira
Koike, Yuta
Kuwatsuka, Yutaka
Ogi, Tomoo
Yamamoto, Yosuke  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0003-1104-2612 (unconfirmed)
Endo, Yuichiro  kyouindb  KAKEN_id
Tamura, Hiroshi  kyouindb  KAKEN_id  orcid https://orcid.org/0000-0002-7740-2732 (unconfirmed)
Utani, Atsushi
著者名の別形: 山本, 洋介
遠藤, 雄一郎
田村, 寛
キーワード: Fibroblasts
Calcification
Deletion mutation
Collagens
Mutation
Reverse transcriptase-polymerase chain reaction
Enzyme-linked immunoassays
Gene expression
発行日: May-2017
出版者: Public Library of Science (PLoS)
誌名: PLOS ONE
巻: 12
号: 5
論文番号: e0177375
抄録: Gamma-glutamyl carboxylase (GGCX) gene mutation causes GGCX syndrome (OMIM: 137167), which is characterized by pseudoxanthoma elasticum (PXE)-like symptoms and coagulation impairment. Here, we present a 55-year-old male with a novel homozygous deletion mutation, c.2, 221delT, p.S741LfsX100, in the GGCX gene. Histopathological examination revealed calcium deposits in elastic fibers and vessel walls, and collagen accumulation in the mid-dermis. Studies of dermal fibroblasts from the patient (GGCX dermal fibroblasts) demonstrated that the mutated GGCX protein was larger, but its expression level and intracellular distribution were indistinguishable from those of the wild-type GGCX protein. Immunostaining and an enzyme-linked immunosorbent assay showed an increase in undercarboxylated matrix gamma-carboxyglutamic acid protein (ucMGP), a representative substrate of GGCX and a potent calcification inhibitor, indicating that mutated GGCX was enzymatically inactive. Under osteogenic conditions, calcium deposition was exclusively observed in GGCX dermal fibroblasts. Furthermore, GGCX dermal fibroblast cultures contained 23- and 7.7-fold more alkaline phosphatase (ALP)-positive cells than normal dermal fibroblast cultures (n = 3), without and with osteogenic induction, respectively. Expression and activity of ALP were higher in GGCX dermal fibroblasts than in normal dermal fibroblasts upon osteogenic induction. mRNA levels of other osteogenic markers were also higher in GGCX dermal fibroblasts than in normal dermal fibroblasts, which including bone morphogenetic protein 6, runt-related transcription factor 2, and periostin (POSTN) without osteogenic induction; and osterix, collagen type I alpha 2, and POSTN with osteogenic induction. Together, these data indicate that GGCX dermal fibroblasts trans-differentiate into the osteogenic lineage. This study proposes another mechanism underlying aberrant calcification in patients with GGCX syndrome.
著作権等: © 2017 Okubo et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
URI: http://hdl.handle.net/2433/267712
DOI(出版社版): 10.1371/journal.pone.0177375
PubMed ID: 28494010
出現コレクション:学術雑誌掲載論文等

アイテムの詳細レコードを表示する

Export to RefWorks


出力フォーマット 


このアイテムは次のライセンスが設定されています: クリエイティブ・コモンズ・ライセンス Creative Commons